人結腸癌細胞KM12

細胞名稱

人結腸癌細胞KM12

貨物編碼

BFN60808853

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   2類

培養體系

90%DMEM+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人結腸癌細胞KM12取自女性供體。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: JFCR39 cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Doubling time: 23 hours (PubMed=25984343); 23.7 hours (NCI-DTP).

Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Misspelling: KIM12; In GEO GSM846361.

基因突變

TPM3-NTRK1 gene fusion (PubMed=24962792; PubMed=25485619).

Homozygous for ACVR2A p.Lys437fs*5 (c.1310delA) (PubMed=12615714).

Heterozygous for APC p.Asn1819fs*7 (c.5454_5455insA) (PubMed=17088437).

BRAF p.Pro403fs (PubMed=28683746).

Heterozygous for BRCA2 p.Asn1784Hisfs*7 (c.5350_5351delAA) (PubMed=17088437).

Heterozygous for PTEN p.Gly129Ter (c.385G>T) and p.Lys267fs*9 (c.800delA) (PubMed=17088437; PubMed=28683746).

Heterozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (PubMed=12615714).

Heterozygous for TP53 p.Arg72fs*51 (c.215delG) (PubMed=17088437; PubMed=28683746).

TP53 p.His179Arg (c.536A>G) (PubMed=15900046).

HLA信息

Class I

HLA-A        A*02

HLA-B        B*07:02:01

HLA-C        C*07:02:01

Class II

HLA-DP        DPB1*13:01

HLA-DQ        DQB1*03:02

HLA-DR        DRB1*04:01:01

STR信息

Amelogenin        X

CSF1PO        10,12

D3S1358        14

D5S818        10,17 (Cosmic-CLP)

10,18 (PubMed=19372543)

10 (PubMed=25877200; PubMed=25926053)

D7S820        8,9 (Cosmic-CLP)

8,8.3 (PubMed=19372543; PubMed=25877200; PubMed=25926053)

D8S1179        11,13

D13S317        12,15

D16S539        11

D18S51        13

D19S433        11,14

D21S11        27

FGA        20,22

Penta D        12

Penta E        14,18

TH01        9.3

TPOX        11,12

vWA        17 (PubMed=11416159)

17,19 (Cosmic-CLP; PubMed=19372543; PubMed=25877200; PubMed=25926053)

參考文獻

PubMed=28683746; DOI=10.1186/s12943-017-0691-y

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Mol. Cancer 16:116-116(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)